Literature DB >> 27497767

Reducing Opioid Misuse: Evaluation of a Medicaid Controlled Substance Lock-In Program.

Asheley Cockrell Skinner1, Chris Ringwalt2, Rebecca B Naumann3, Andrew W Roberts4, Leslie A Moss5, Nidhi Sachdeva6, Mark A Weaver7, Joel Farley8.   

Abstract

Opioid misuse, abuse, and overdose are a rapidly growing public health epidemic. Medicaid Lock-In Programs (MLIPs) are designed to prevent overutilization of controlled substances by Medicaid patients. However, despite widespread use, there is little information on their effect. Using North Carolina (NC) Medicaid claims data from October 2008 through June 2013, we examined changes in Medicaid-reimbursed opioid prescriptions by patients enrolled in NC's MLIP. We used mixed effects models to examine the effect of MLIP enrollment on monthly opioid claims, number of pharmacies, total days' supply, total units (ie, pills), and total Medicaid payments for opioids. In our sample of 6,148 MLIP patients, the odds of having any opioid claim in a given month was 84% lower during MLIP enrollment relative to the period before enrollment (odds ratio = .16). MLIP enrollment also corresponded with a reduction in monthly number of opioid prescriptions by 1.13, monthly number of pharmacies by .61, and monthly Medicaid expenditures by $22.78. Although MLIPs may constitute a successful component of comprehensive efforts to reduce the potential overutilization of opioids, care should be taken to ensure that programs such as MLIPs do not constrain patients' legitimate needs for analgesic medications. PERSPECTIVE: Enrollment in NC's MLIP reduced the likelihood that patients would present a claim for an opioid prescription, and the number of opioid prescriptions patients secured each month. MLIPs may constitute a successful strategy for reducing the misuse, abuse, and diversion of prescription opioids. However, further research is needed to examine the program's potential unintended consequences. Copyright Â
© 2016 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Medicaid; Opioids; controlled substances; managed care; utilization

Mesh:

Year:  2016        PMID: 27497767      PMCID: PMC7262688          DOI: 10.1016/j.jpain.2016.07.003

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  13 in total

Review 1.  Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence.

Authors:  Joel Lexchin; Paul Grootendorst
Journal:  Int J Health Serv       Date:  2004       Impact factor: 1.663

2.  Drug-poisoning deaths involving heroin: United States, 2000-2013.

Authors:  Holly Hedegaard; Li-Hui Chen; Margaret Warner
Journal:  NCHS Data Brief       Date:  2015-03

Review 3.  Assessing the present state and potential of Medicaid controlled substance lock-in programs.

Authors:  Andrew W Roberts; Asheley Cockrell Skinner
Journal:  J Manag Care Spec Pharm       Date:  2014-05

4.  Combating the prescription painkiller epidemic: a national prescription drug reporting program.

Authors:  Joanna Shepherd
Journal:  Am J Law Med       Date:  2014

5.  Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

Authors:  Rose A Rudd; Noah Aleshire; Jon E Zibbell; R Matthew Gladden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

6.  Economic costs of nonmedical use of prescription opioids.

Authors:  Ryan N Hansen; Gerry Oster; John Edelsberg; George E Woody; Sean D Sullivan
Journal:  Clin J Pain       Date:  2011 Mar-Apr       Impact factor: 3.442

7.  Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010.

Authors:  Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2013-02-12       Impact factor: 4.492

8.  Societal costs of prescription opioid abuse, dependence, and misuse in the United States.

Authors:  Howard G Birnbaum; Alan G White; Matt Schiller; Tracy Waldman; Jody M Cleveland; Carl L Roland
Journal:  Pain Med       Date:  2011-03-10       Impact factor: 3.750

9.  Patterns of abuse among unintentional pharmaceutical overdose fatalities.

Authors:  Aron J Hall; Joseph E Logan; Robin L Toblin; James A Kaplan; James C Kraner; Danae Bixler; Alex E Crosby; Leonard J Paulozzi
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

10.  Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims.

Authors:  Anupam B Jena; Dana Goldman; Lesley Weaver; Pinar Karaca-Mandic
Journal:  BMJ       Date:  2014-02-19
View more
  5 in total

1.  Evaluation of a Medicaid Lock-in Program: Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk.

Authors:  Rebecca B Naumann; Andrew W Roberts; Stephen W Marshall; Asheley C Skinner
Journal:  Med Care       Date:  2019-03       Impact factor: 2.983

2.  Health Care Utilization and Comorbidity History of North Carolina Medicaid Beneficiaries in a Controlled Substance "Lock-in" Program.

Authors:  Rebecca B Naumann; Stephen W Marshall; Jennifer L Lund; Asheley C Skinner; Christopher Ringwalt; Nisha C Gottfredson
Journal:  N C Med J       Date:  2019 May-Jun

3.  A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018.

Authors:  Bahareh Ansari; Katherine M Tote; Eli S Rosenberg; Erika G Martin
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

Review 4.  The state of the science in opioid policy research.

Authors:  Megan S Schuler; Sara E Heins; Rosanna Smart; Beth Ann Griffin; David Powell; Elizabeth A Stuart; Bryce Pardo; Sierra Smucker; Stephen W Patrick; Rosalie Liccardo Pacula; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2020-06-27       Impact factor: 4.492

5.  Evidence for state, community and systems-level prevention strategies to address the opioid crisis.

Authors:  Tamara M Haegerich; Christopher M Jones; Pierre-Olivier Cote; Amber Robinson; Lindsey Ross
Journal:  Drug Alcohol Depend       Date:  2019-09-19       Impact factor: 4.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.